CHINA 32 recovered patients donate plasma to others with coronavirus infection

CHINA

32 recovered patients donate plasma to others with coronavirus infection

China Daily

13:10, February 16, 2020


微信图片_20200216130901.jpg

A recovered female patient (right) returns to the hospital to donate blood in Guangzhou, Guangdong province, on Feb 14. [Photo/Xinhua]

Thirty-two patients who have recovered from the novel coronavirus had donated 10,650 ml of plasma by Saturday, said China National Biotec Group, a state-owned biological products maker.

The donation came one day after the company announced on Friday that it has developed convalescent plasma to treat patients with novel coronavirus pneumonia.

The current treatment of novel coronavirus pneumonia lacks vaccines and specific drugs, but recovered patients’ plasma has been put into clinical treatment which achieved initial results.

The company said they have set up a special team to collect plasma from recovered patients in Wuhan, Central China’s Hubei province, since Jan 20.

On Feb 8, three critically ill patients in a hospital in the Jiangxia District of Wuhan received plasma treatment. More than 10 critical patients received the treatment so far, the company said.

The clinical results showed that patients’ clinical symptoms have improved significantly 12 to 24 hours after the treatment, with inflammatory indicators in the laboratory decreasing significantly and some key indicators, such blood oxygen saturation, showingn promising results.

Convalescent plasma has also been proved effective in the treatment of severe acute respiratory syndrome and Ebola virus disease.

Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue